- Home
- HBB vs STRO Comparison
HBB vs STRO Comparison
Compare HBB & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- STRO
- Stock Information
- Founded
- HBB 1904
- STRO 2003
- Country
- HBB United States
- STRO United States
- Employees
- HBB N/A
- STRO N/A
- Industry
- HBB Home Furnishings
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HBB Consumer Discretionary
- STRO Health Care
- Exchange
- HBB Nasdaq
- STRO Nasdaq
- Market Cap
- HBB 292.6M
- STRO 292.6M
- IPO Year
- HBB 2017
- STRO 2018
- Fundamental
- Price
- HBB $19.94
- STRO $2.73
- Analyst Decision
- HBB
- STRO Strong Buy
- Analyst Count
- HBB 0
- STRO 7
- Target Price
- HBB N/A
- STRO $12.14
- AVG Volume (30 Days)
- HBB 67.1K
- STRO 888.5K
- Earning Date
- HBB 10-30-2024
- STRO 11-13-2024
- Dividend Yield
- HBB 2.38%
- STRO N/A
- EPS Growth
- HBB 107.04
- STRO N/A
- EPS
- HBB 1.88
- STRO N/A
- Revenue
- HBB $647,834,000.00
- STRO $160,955,000.00
- Revenue This Year
- HBB $4.60
- STRO N/A
- Revenue Next Year
- HBB N/A
- STRO N/A
- P/E Ratio
- HBB $10.32
- STRO N/A
- Revenue Growth
- HBB 5.30
- STRO 230.90
- 52 Week Low
- HBB $14.34
- STRO $2.45
- 52 Week High
- HBB $31.78
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- HBB 27.83
- STRO 39.12
- Support Level
- HBB $18.62
- STRO $2.55
- Resistance Level
- HBB $20.11
- STRO $2.76
- Average True Range (ATR)
- HBB 0.91
- STRO 0.27
- MACD
- HBB 0.19
- STRO -0.05
- Stochastic Oscillator
- HBB 16.21
- STRO 18.51
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.